Alveus Therapeutics is a clinical-stage biotech company developing therapies for obesity and metabolic diseases.
Alveus Therapeutics has raised $197.0M in total funding. The most recent round was Series A. The last funding was announced in January 2026.
Alveus Therapeutics's investors include Andera Partners, Sanofi, Novo Holdings, Kurma Partners, Jeito Capital.
Alveus Therapeutics is headquartered in Philadelphia, United States.
Alveus Therapeutics is a clinical-stage biotech company developing therapies for obesity and metabolic diseases.
Alveus Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Alveus Therapeutics — Funding & Investors." VCBacked, January 8, 2026, https://www.vcbacked.co/company/alveus-therapeutics. Accessed October 30, 2026.
VCBacked. (2026). Alveus Therapeutics — Funding & Investors. Retrieved October 30, 2026, from https://www.vcbacked.co/company/alveus-therapeutics
{{cite web |title=Alveus Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/alveus-therapeutics |website=VCBacked |access-date=October 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated